Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13406669 | 1.00 | L3MBTL1 (0.39) | L3MBTL1DRD2DRD3CHRM4CHRM5 | |
| SCHEMBL14234019 | 0.94 | L3MBTL1 (0.35) | L3MBTL1 | |
| SCHEMBL14310363 | 0.82 | CHRM3 (0.32) | CHRM3 | |
| SCHEMBL8350061 | 0.82 | CHRM3 (0.32) | CHRM3 | |
| SCHEMBL16864502 | 0.79 | — | — | |
| SCHEMBL16542281 | 0.78 | — | — | |
| SCHEMBL17346685 | 0.78 | CHRM4 (0.31) | CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27927683 | 0.77 | SHBG (0.30) | — | |
| SCHEMBL13850386 | 0.76 | PARP1 (0.32) | — | |
| SCHEMBL6108591 | 0.76 | PARP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160156204-A1 | BATTERY PACK | SAMSUNG SDI CO., LTD. (KR) | 2016-06-02 | — | — | US | disclosed |
| US-20110142941-A1 | Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof | NANOPHARMACEUTICALS LLC | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142941-A1 | Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof | TSHR, THRA, TRHR | L3MBTL1 2829/4885DRD2 2489/4885DRD3 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.